Organic Active Ingredients TRIZ Cases

A sterol ester topical composition manages psoriasis symptoms through skin cell regulation and inflammation reduction.

Benzoxazinone amides reduce hyperkalemia risk by selectively targeting vascular endothelial mineralocorticoid receptors.

Purified mushroom beta glucan increases neuronal viability and reduces amyloid cytotoxicity to treat cognitive dysfunction.

A triple-combination pharmaceutical composition merges anti-LAG-3 antibodies, PD-1 pathway inhibitors, and immunotherapeutic agents.

Pyrazolo[3,4-b]pyridine ethynyl derivatives inhibit GCN2 while maintaining solubility and bioavailability for cancer treatment.

Segmented cannabis composition combines buccal absorption with gastric release to overcome low aqueous solubility.

Administering BMP signaling inhibitors rescues neural precursor defects, reduces astrogliosis, and delays cognitive impairment by modulating receptor activity.

A sustained-release matrix encapsulates denervation drugs for gradual neural ablation.

Segmented hyaluronic acid and chondroitin sulfate resolve viscosity-penetration contradictions to treat interstitial cystitis.

Anhydrous perampanel polymorphs resolve bioavailability trade-offs by enhancing stability via controlled crystallization.

Modified peptide backbones reduce liver accumulation and improve renal excretion while maintaining high affinity binding to integrin alpha v beta 3.

Inhibiting ACAT1 elevates plasma membrane cholesterol to enhance CD8+ T cell proliferation and cytotoxicity, overcoming tumor microenvironment suppression.

Phosphatidylcholine liposomes transport cannabinoids across the blood-brain barrier, reducing side effects while treating epilepsy and Alzheimer's disease.

MARK2 inhibitors reduce eIF2α phosphorylation, alleviating proteotoxic stress associated with neurodegenerative diseases.

Cyclic phosphate substituted nucleoside compounds inhibit viral replication through targeted structural modification.

Controlled melt recrystallization yields stable pharmaceutical compositions resistant to environmental degradation.

LDL nanoparticles deliver docosahexaenoic acid to malignant cells, overcoming poor solubility and rapid clearance.

Pre-hardening stage adsorption boosts drug capacity in echogenic microcapsules while maintaining acoustic contrast.

A herbal composition combining Hovenia, valerian root, and Panax notoginseng extracts to promote sleep.

23-OH ursolic acid attenuates monocyte hypersensitivity by inhibiting chemokine-induced activation, addressing inadequate treatment for vascular complications.

Immobilized fibrinogen-binding peptides on cross-linked polysaccharide particles enable sterilization-stable bleeding control without viral infectivity risks.

Systematic variation of crystallization parameters generates stable solid forms of the JNK inhibitor, optimizing solubility for treating fibrotic disorders.

Indoxyl sulfate selectively targets colon cancer cells via oxidative stress while sparing normal colonic tissue.

A suprachoroidal delivery device uses a gas reservoir and force element to push active agents through a hollow needle into the eye.

Novel antiviral prodrug structure metabolizes to triphosphate PSI-7409 in mammalian liver.

Peptides bind CD40 to block CD154 interaction, resolving the trade-off between effective inhibition and immune rejection in transplant settings.

Developing specific crystal forms and hydrates of orbit azine-fumarate addresses drug resistance while maintaining therapeutic efficacy.

Novel pyridine and pyrazine derivatives inhibit Axl and c-Met receptor tyrosine kinases to treat cell proliferative disorders.

Epidural MCOPPB administration reduces pain intensity while avoiding adverse side effects common with opioids.

Modified fused pyrimidine compounds overcome drug resistance mutations in HIV by inhibiting reverse transcriptase.

Peripherally restricted mu and delta opioid agonists reduce respiratory depression and addiction risks while maintaining potent pain relief.

Corticosteroid pre-treatment enables lower initial antibody dosing to reduce infusion-related reactions.

A 5-membered heterocyclic compound reversibly inhibits proton pumps to suppress gastric acid secretion.

YM-08 neutral pyridine structure crosses the blood-brain barrier and reduces renal accumulation while maintaining Hsp70 affinity.

One-step synthesis of phosphate-based enzyme inhibitors using o-phosphorylethanolamine and acyl chlorides.

Novel macrocyclic chalcone-amide compounds inhibit PLpro enzymatic activity to reduce viral replication.

EHop-016 resolves low potency in metastatic cancer by binding the Rac1 GEF pocket, achieving 1.1 μM IC50 while maintaining cell viability.

Activating the EGFR pathway compensates for dystrophin deficiency, restoring cell polarity and enabling asymmetric division in satellite stem cells.

PEG oligomer conjugation modifies opioid agonists to reduce blood-brain barrier penetration and first-pass metabolism while retaining analgesic activity.

Quinoline derivatives modulate PAPD5 and PAPD7 enzymes to enhance TERC levels, addressing the lack of effective inhibitors for telomere-associated diseases.

Engineered supercharged green fluorescence protein carriers link payload molecules to avascular tissues via localized positive charge clusters.

Anhydrous orvepitant maleate Form 1 eliminates hygroscopicity and solvated impurities through controlled phase transitions.

A lipid nanoparticle delivers nucleic acids and photosensitizers to cancer cells.

Specific thiazole crystal forms A and B provide stable antiviral activity against herpes simplex virus while reducing host cell DNA damage.

A polyisoprene condom surface coated with hydrophilic adjuvants and nitric oxide prodrugs for continuous active ingredient release.

Segmented enteric coatings shield oral rapamycin nanoparticles from gastrointestinal degradation, ensuring reliable systemic delivery.

Halogenated nucleoside prodrugs target viral RNA polymerase to enhance bioavailability, addressing the lack of effective aerosol exposure treatments.

Prodrug P18 segments the inhibitor to cross the blood-brain barrier, resolving poor pharmacokinetics.